WallStreetZenWallStreetZen

AnalystsAlex Thompson
Alex Thompson's Stock Forecasts

Analyst Ranking
Top 19%
#871 out of 4563 analysts
Average Return
+10.84%
Win Rate
42%10 out of 24
Risk vs Reward
Poor
Good

Alex Thompson's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Dice Therapeutics IncDICE
+126.21%$21.02$47.55
2022-09-07 -
2023-08-08
Strong Buy
Spyre Therapeutics IncSYRE
+123.71%$14.75$32.99
2023-07-25 -
2024-04-24
Strong Buy
Chinook Therapeutics IncKDNY
+110.51%$17.99$37.87
2022-06-28 -
2023-06-13
Strong Buy
Immunovant IncIMVT
+108.86%$15.47$32.31
2023-03-30 -
2024-03-28
Strong Buy
Spyre Therapeutics IncSYRE
+108.67%$15.81$32.99
2023-12-18 -
2024-04-24
Strong Buy

Alex Thompson's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Spyre Therapeutics IncSYRE
3Strong Buy$54.00+63.69%Reiterates
a month ago
Dianthus Therapeutics IncDNTH
1Strong Buy$44.00+106.38%Initiates Coverage On
2 months ago
Ventyx Biosciences IncVTYX
5Hold$2.00-52.83%Maintains
4 months ago
Travere Therapeutics IncTVTX
2Hold$10.00+83.49%Maintains
4 months ago
Moonlake ImmunotherapeuticsMLTX
2Strong Buy$69.00+62.62%Maintains
4 months ago
Argenx SeARGX
3Strong Buy$560.00+49.33%Maintains
4 months ago
Aclaris Therapeutics IncACRS
4Hold$1.00-14.53%Maintains
4 months ago
Morphic Holding IncMORF
3Hold$33.00+19.18%Maintains
7 months ago
Viridian Therapeutics IncVRDN
2Strong Buy$40.00+206.98%Reiterates
7 months ago
Rapt Therapeutics IncRAPT
1Strong Buy$40.00+406.33%Initiates Coverage On
9 months ago
Immunovant IncIMVT
2Strong Buy$34.00+18.06%Maintains
9 months ago
Chinook Therapeutics IncKDNY
3Hold$41.00+1.51%Downgrades
10 months ago
Pliant Therapeutics IncPLRX
1Strong Buy$33.00N/AInitiates Coverage On
a year ago
Dice Therapeutics IncDICE
1Strong Buy$37.00N/AInitiates Coverage On
2 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.